OTLC
What one share of Oncotelic Therapeutics holds
Pharmaceutical Preparations
Oncotelic Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | $0.56 |
|---|---|
| Cash and investments | $0.00 |
| Debt | $0.00 |
| Book value | $0.58 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$0.51 | — | −$0.57 | — | $0.47 |
| 2017 | — | −$0.52 | — | −$0.41 | — | −$0.02 |
| 2018 | — | −$0.12 | — | −$0.04 | — | $0.36 |
| 2019 | — | −$0.11 | — | −$0.04 | — | $0.20 |
| 2020 | $0.02 | −$0.11 | — | −$0.03 | — | $0.13 |
| 2021 | — | −$0.03 | — | −$0.01 | — | $0.02 |
| 2022 | — | $0.01 | — | −$0.00 | — | $0.05 |
| 2023 | $0.00 | −$0.02 | — | −$0.00 | — | $0.03 |
| 2024 | — | −$0.01 | — | −$0.00 | — | $0.02 |
| 2025 | — | $0.59 | — | −$0.00 | — | $0.59 |